GlassScriptPhysician profile
Matthew T Stevenson
NPI 1699975649
$506.55
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $125 · 2021: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $141.70 | 2021 | |
| Ucb, INC. | $79.58 | 2019-2021 | |
| Allergan, INC. | $58.00 | 2019-2021 | |
| Lilly USA, LLC | $33.54 | 2019-2020 | |
| Ge Healthcare | $32.32 | 2019-2020 | |
| Amgen INC. | $28.77 | 2020 | |
| Supernus Pharmaceuticals, INC. | $26.77 | 2019-2020 | |
| Greenwich Biosciences, INC. | $26.27 | 2019 | |
| Abbvie INC. | $21.93 | 2021 | |
| Sk Life Science, INC. | $20.58 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.